AP3521A - Crystalline forms of hydrochloride salt of (4a-r,9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1h-indeno [2,1-b]pyridine-6-carbonitrile and their use as hsd 1 inhibitors - Google Patents

Crystalline forms of hydrochloride salt of (4a-r,9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1h-indeno [2,1-b]pyridine-6-carbonitrile and their use as hsd 1 inhibitors

Info

Publication number: AP3521A
Authority: AP; ARIPO
Prior art keywords: benzoimidazole; indeno; hsd; carbonitrile; hexahydro
Prior art date: 2010-11-05

Application number

AP2013006902A

Other languages

English (en)

Other versions

AP2013006902A0 (en

Inventor

Matthias Eckhardt

Hans-Juergen Martin

Martin Schuehle

Sandra Sick

Bing-Shiou Yang

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-05

Filing date

2011-11-04

Publication date

2016-01-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44999935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3521(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-11-05 Priority claimed from PCT/US2010/055586 external-priority patent/WO2011057054A1/en

2011-11-04 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2013-06-30 Publication of AP2013006902A0 publication Critical patent/AP2013006902A0/xx

2016-01-11 Application granted granted Critical

2016-01-11 Publication of AP3521A publication Critical patent/AP3521A/xx

Links

QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 title 1
101100451537 Caenorhabditis elegans hsd-1 gene Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AP2013006902A 2010-11-05 2011-11-04 Crystalline forms of hydrochloride salt of (4a-r,9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1h-indeno [2,1-b]pyridine-6-carbonitrile and their use as hsd 1 inhibitors AP3521A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/US2010/055586 WO2011057054A1 (en)	2009-11-06	2010-11-05	Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
US201161484995P	2011-05-11	2011-05-11
PCT/US2011/059331 WO2012061708A1 (en)	2010-11-05	2011-11-04	Crystalline forms of hydrochloride salt of (4a-r,9a-s) -1- (1h - benzoimidazole- 5 -carbonyl) -2, 3, 4, 4a, 9, 9a - hexahydro -1h- indeno [2, 1 -b] pyridine- 6 -carbonitrile and their use as hsd 1 inhibitors

Publications (2)

Publication Number	Publication Date
AP2013006902A0 AP2013006902A0 (en)	2013-06-30
AP3521A true AP3521A (en)	2016-01-11

Family

ID=44999935

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2013006902A AP3521A (en)	2010-11-05	2011-11-04	Crystalline forms of hydrochloride salt of (4a-r,9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1h-indeno [2,1-b]pyridine-6-carbonitrile and their use as hsd 1 inhibitors

Country Status (36)

Country	Link
US (2)	US8686149B2 (xx)
EP (1)	EP2635563B1 (xx)
JP (1)	JP2013541592A (xx)
KR (1)	KR20130119939A (xx)
CN (1)	CN103228642B (xx)
AP (1)	AP3521A (xx)
AR (1)	AR083678A1 (xx)
AU (1)	AU2011323164B2 (xx)
BR (1)	BR112013011095A2 (xx)
CA (1)	CA2816136A1 (xx)
CL (1)	CL2013001221A1 (xx)
CO (1)	CO6781480A2 (xx)
CY (1)	CY1116043T1 (xx)
DK (1)	DK2635563T3 (xx)
EA (1)	EA022406B1 (xx)
EC (2)	ECSP12011788A (xx)
ES (1)	ES2533833T3 (xx)
GE (1)	GEP20166481B (xx)
HR (1)	HRP20150327T1 (xx)
IL (1)	IL225647A0 (xx)
ME (1)	ME02066B (xx)
MX (1)	MX2013005069A (xx)
NZ (1)	NZ609281A (xx)
PE (1)	PE20140123A1 (xx)
PH (1)	PH12013500879A1 (xx)
PL (1)	PL2635563T3 (xx)
PT (1)	PT2635563E (xx)
RS (1)	RS53900B1 (xx)
SG (1)	SG189859A1 (xx)
SI (1)	SI2635563T1 (xx)
SM (1)	SMT201500095B (xx)
TN (1)	TN2012000117A1 (xx)
TW (1)	TWI537258B (xx)
UA (1)	UA110807C2 (xx)
UY (1)	UY33701A (xx)
WO (1)	WO2012061708A1 (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009063061A2 (en)	2007-11-16	2009-05-22	Boehringer Ingelheim International Gmbh	Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
CA2724214A1 (en)	2008-05-13	2009-11-19	Boehringer Ingelheim International Gmbh	Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
US8703765B2 (en)	2009-06-02	2014-04-22	Boehringer Ingelheim International Gmbh	Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
EP2440537A1 (en)	2009-06-11	2012-04-18	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
WO2011159760A1 (en)	2010-06-16	2011-12-22	Vitae Pharmaceuticals, Inc.	Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
TWI537258B (zh)	2010-11-05	2016-06-11	百靈佳殷格翰國際股份有限公司	六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物
US8735585B2 (en)	2011-08-17	2014-05-27	Boehringer Ingelheim International Gmbh	Indenopyridine derivatives
CA2872932A1 (en) *	2012-05-09	2013-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical combinations for the treatment of metabolic disorders
EP3235813A1 (en)	2016-04-19	2017-10-25	Cidqo 2012, S.L.	Aza-tetra-cyclo derivatives
WO2019043217A1 (en)	2017-09-04	2019-03-07	F. Hoffmann-La Roche Ag	DIHYDROBENZIMIDAZOLONES
CN113557235B (zh)	2019-03-06	2025-08-08	C4医药公司	用于药物治疗的杂环化合物
CN118005644B (zh) *	2024-01-29	2025-12-16	中国科学院南海海洋研究所	十氢芴型生物碱及其制备方法和在制备抗菌药物中应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009063061A2 (en) *	2007-11-16	2009-05-22	Boehringer Ingelheim International Gmbh	Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL127995C (xx)	1963-12-20		Geigy Ag J R
US3341538A (en)	1965-06-18	1967-09-12	Geigy Chem Corp	Certain 2, 6-methano-3-benzazocines
DE1785124A1 (de)	1968-08-13	1971-11-11	Prym Werke William	Reissverschluss
DE2108954A1 (en)	1971-02-25	1972-09-07	Boehringer Sohn Ingelheim	2-(furylmethyl)-6,7-benzomorphans - useful as cns active agents
GB1304175A (xx)	1969-03-31	1973-01-24
DE2105743C3 (de)	1971-02-08	1979-11-29	Boehringer Sohn Ingelheim	2-(Furylmethyl)- a -5,9-dialkyl -6,7benzomorphane, Verfahren zu ihrer Herstellung und deren Verwendung
US3681349A (en)	1970-03-05	1972-08-01	Morton Norwich Products Inc	1-(substituted benzyl) tetrahydro-2-(1h) pyrimidones
US3657257A (en)	1970-08-31	1972-04-18	Robins Co Inc A H	3-aryl-8-carbamoyl nortropanes
DE2229695A1 (de)	1972-06-19	1974-01-31	Boehringer Sohn Ingelheim	2-(heteroaryl-methyl)-5,9 beta-dialkyl6,7-benzomorphane, deren saeureadditionssalze sowie verfahren zu deren herstellung
DE2338369A1 (de)	1973-07-26	1975-02-13	Schering Ag	Mikrobiologische hydroxylierung von 2,6-methano-3-benzazocinen
SU510999A3 (ru)	1973-10-27	1976-04-15	К.Х.Берингер Зон, (Фирма)	Способ получени (метоксиметил-фурилметил)6,7-бензоморфанов илиморфинанов
US4009171A (en)	1974-02-21	1977-02-22	Sterling Drug Inc.	N-acylated-11-oxygenated-2,6-methano-3-benzazocine intermediates
US4087532A (en)	1974-03-09	1978-05-02	Boehringer Ingelheim Gmbh	Analgesically useful 2-tetrahydrofurfuryl-5-lower alkyl-2-oxy-6,7-benzomorphans and salts thereof
DE2411382C3 (de)	1974-03-09	1979-09-06	C.H. Boehringer Sohn, 6507 Ingelheim	2-Tetrahydrofurfuryl-6,7-benzomorphane, Verfahren zur Herstellung und deren Verwendung
DE2437610A1 (de)	1974-08-05	1976-02-26	Boehringer Sohn Ingelheim	Neue 5,9-beta-disubstituierte 2-tetrahydrofurfuryl-6,7-benzomorphane, deren saeureadditionssalze, ihre verwendung als arzneimittel und verfahren zu deren herstellung
US4108857A (en)	1975-08-18	1978-08-22	Sterling Drug Inc.	Imidazolylmethyl methanobenzazocines
DE2828039A1 (de)	1978-06-26	1980-01-10	Boehringer Sohn Ingelheim	2-(2-alkoxyethyl)-2'-hydroxy-6,7-benzomorphane deren saeureadditionssalze diese enthaltende arzneimittel und verfahren zu deren herstellung
GB9510459D0 (en)	1995-05-24	1995-07-19	Zeneca Ltd	Bicyclic amines
GB9517622D0 (en)	1995-08-29	1995-11-01	Univ Edinburgh	Regulation of intracellular glucocorticoid concentrations
CA2262502C (en)	1996-07-31	2002-11-26	Nikken Chemicals Co., Ltd.	6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same
GB9623944D0 (en)	1996-11-15	1997-01-08	Zeneca Ltd	Bicyclic amine derivatives
US6514977B1 (en)	1997-05-22	2003-02-04	G.D. Searle & Company	Substituted pyrazoles as p38 kinase inhibitors
YU54202A (sh)	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
WO2001055063A1 (en)	2000-01-25	2001-08-02	Idemitsu Petrochemical Co., Ltd.	Novel bisadamantane compounds, process for preparing the same, and novel biadamantane derivatives
DE10034623A1 (de)	2000-07-17	2002-01-31	Bayer Ag	Heterocyclisch substituierte Pyridine als Cytokin-Inhibitoren
CN1653050B (zh)	2002-05-17	2013-04-24	詹肯生物科学公司	阿片和阿片样化合物及其用途
US7135575B2 (en) *	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
EP1610789B1 (en)	2003-03-26	2010-07-21	Merck Sharp & Dohme Corp.	Bicyclic piperidine derivatives as melanocortin-4 receptor agonists
US7700583B2 (en)	2003-04-11	2010-04-20	High Point Pharmaceuticals, Llc	11β-hydroxysteroid dehydrogenase type 1 active compounds
EP1615698B1 (en) *	2003-04-11	2010-09-29	High Point Pharmaceuticals, LLC	New amide derivatives and pharmaceutical use thereof
KR101193464B1 (ko)	2004-05-07	2012-10-24	얀센 파마슈티카 엔.브이.	１１-베타 하이드록시스테로이드 탈수소효소 저해제로서의아다만틸 피롤리딘-２-온 유도체
MY141198A (en)	2004-08-30	2010-03-31	Janssen Pharmaceutica Nv	Tricyclic adamantylamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
EP1802623A1 (en)	2004-10-12	2007-07-04	Novo Nordisk A/S	11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
AU2005296124A1 (en)	2004-10-13	2006-04-27	Neurogen Corporation	Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor
WO2006104280A1 (ja)	2005-03-31	2006-10-05	Takeda Pharmaceutical Company Limited	糖尿病の予防・治療剤
JP2009514818A (ja)	2005-11-01	2009-04-09	ハイポイントファーマシューティカルズ，リミティドライアビリティカンパニー	置換アミドの製薬学的用途
AU2006310519A1 (en)	2005-11-01	2007-05-10	High Point Pharmaceuticals, Llc	Pharmaceutical use of substituted amides
JP2007140188A (ja)	2005-11-18	2007-06-07	Fujifilm Corp	ポジ型感光性組成物及びそれを用いたパターン形成方法
WO2007076055A2 (en)	2005-12-22	2007-07-05	Entremed, Inc.	Compositions and methods comprising proteinase activated receptor antagonists
US8865707B2 (en)	2005-12-30	2014-10-21	Merck Sharp & Dohme Corp.	Cholesteryl ester transfer protein inhibitors
EA200870216A1 (ru)	2006-01-31	2009-02-27	Инсайт Корпорейшн	Амидо соединения и их применение в качестве лекарственных средств
AU2007240458B2 (en)	2006-04-21	2012-03-15	Eli Lilly And Company	Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1
EP2029529B1 (en)	2006-04-24	2010-07-07	Eli Lilly & Company	Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
AU2007244861B2 (en)	2006-04-25	2012-03-15	Eli Lilly And Company	Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PE20080344A1 (es)	2006-06-27	2008-06-09	Sanofi Aventis	Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1
US8132151B2 (en)	2006-07-18	2012-03-06	Yahoo! Inc.	Action tags
MX2009003939A (es)	2006-10-19	2009-05-11	Hoffmann La Roche	Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes.
TW200829171A (en)	2006-11-17	2008-07-16	Nihon Nohyaku Co Ltd	Haloalkyl sulfonanilide derivatives or salts thereof, herbicide using it as effective constituent and use-method thereof
EP1935420A1 (en)	2006-12-21	2008-06-25	Merck Sante	2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
CA2678577A1 (en)	2007-02-26	2008-09-04	Vitae Pharmaceuticals, Inc.	Cyclic urea and carbamate inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
BRPI0721430A2 (pt)	2007-03-09	2013-01-08	High Point Pharmaceuticals Llc	amidas indol e benzimidazol como inibidoras de hidroxiesteràide deidrogenase
CL2008002199A1 (es)	2007-07-26	2009-10-23	Vitae Pharmaceuticals Inc	Compuestos derivados de 1,3-oxazin-2-ona; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad asociada con la actividad de la 11beta-hidroxiesteroide deshidrogenasa tipo 1 (11beta-hsd1) tales como dislipidemia, hiperlipidemia, hipertension, obesidad y enfermedad cardiovascular, entre otras.
AR069207A1 (es)	2007-11-07	2010-01-06	Vitae Pharmaceuticals Inc	Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2714532A1 (en)	2008-02-11	2009-08-20	Vitae Pharmaceuticals, Inc.	1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
CA2711757C (en)	2008-02-12	2016-07-26	Boehringer Ingelheim International Gmbh	Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
JP5730021B2 (ja)	2008-02-15	2015-06-03	ヴァイティーファーマシューティカルズ，インコーポレイテッド	１１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤としてのシクロアルキルラクタム誘導体
JP5538356B2 (ja)	2008-03-18	2014-07-02	ヴァイティーファーマシューティカルズ，インコーポレイテッド	１１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
WO2009134387A1 (en)	2008-05-01	2009-11-05	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
BRPI0911764A2 (pt)	2008-05-01	2015-10-06	Boehringer Ingelheim Int	inibidores cíclicos de 11beta-hidroxiesteroide desigrogenase 1
JP5777030B2 (ja)	2008-07-25	2015-09-09	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	１１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
KR20110050459A (ko)	2008-07-25	2011-05-13	비타이 파마슈티컬즈, 인코포레이티드	11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
US8057970B2 (en)	2008-09-01	2011-11-15	D2S, Inc.	Method and system for forming circular patterns on a surface
MA33216B1 (fr)	2009-04-30	2012-04-02	Boehringer Ingelheim Int	Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
AR078887A1 (es) *	2009-11-06	2011-12-07	Boehringer Ingelheim Int	Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina y composiciones farmaceuticas que los contienen.
TWI537258B (zh)	2010-11-05	2016-06-11	百靈佳殷格翰國際股份有限公司	六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物

2011
- 2011-10-18 TW TW100137675A patent/TWI537258B/zh not_active IP Right Cessation
- 2011-11-01 UY UY0001033701A patent/UY33701A/es not_active Application Discontinuation
- 2011-11-01 AR ARP110104053A patent/AR083678A1/es unknown
- 2011-11-04 SI SI201130449T patent/SI2635563T1/sl unknown
- 2011-11-04 SG SG2013026430A patent/SG189859A1/en unknown
- 2011-11-04 WO PCT/US2011/059331 patent/WO2012061708A1/en not_active Ceased
- 2011-11-04 PT PT117852327T patent/PT2635563E/pt unknown
- 2011-11-04 AU AU2011323164A patent/AU2011323164B2/en not_active Ceased
- 2011-11-04 KR KR1020137014295A patent/KR20130119939A/ko not_active Withdrawn
- 2011-11-04 MX MX2013005069A patent/MX2013005069A/es unknown
- 2011-11-04 CA CA2816136A patent/CA2816136A1/en not_active Abandoned
- 2011-11-04 NZ NZ609281A patent/NZ609281A/en not_active IP Right Cessation
- 2011-11-04 HR HRP20150327TT patent/HRP20150327T1/hr unknown
- 2011-11-04 UA UAA201307042A patent/UA110807C2/uk unknown
- 2011-11-04 RS RS20150205A patent/RS53900B1/sr unknown
- 2011-11-04 CN CN201180053044.5A patent/CN103228642B/zh not_active Expired - Fee Related
- 2011-11-04 AP AP2013006902A patent/AP3521A/xx active
- 2011-11-04 US US13/289,418 patent/US8686149B2/en active Active
- 2011-11-04 JP JP2013537864A patent/JP2013541592A/ja active Pending
- 2011-11-04 GE GEAP201113105A patent/GEP20166481B/en unknown
- 2011-11-04 ME MEP-2015-42A patent/ME02066B/me unknown
- 2011-11-04 EA EA201390643A patent/EA022406B1/ru not_active IP Right Cessation
- 2011-11-04 DK DK11785232.7T patent/DK2635563T3/en active
- 2011-11-04 PH PH1/2013/500879A patent/PH12013500879A1/en unknown
- 2011-11-04 BR BR112013011095A patent/BR112013011095A2/pt not_active IP Right Cessation
- 2011-11-04 EP EP11785232.7A patent/EP2635563B1/en active Active
- 2011-11-04 ES ES11785232.7T patent/ES2533833T3/es active Active
- 2011-11-04 PE PE2013000949A patent/PE20140123A1/es not_active Application Discontinuation
- 2011-11-04 PL PL11785232T patent/PL2635563T3/pl unknown
2012
- 2012-03-16 TN TNP2012000117A patent/TN2012000117A1/en unknown
- 2012-04-05 EC ECSP12011788 patent/ECSP12011788A/es unknown
2013
- 2013-04-09 IL IL225647A patent/IL225647A0/en unknown
- 2013-05-03 CL CL2013001221A patent/CL2013001221A1/es unknown
- 2013-05-30 CO CO13132839A patent/CO6781480A2/es active IP Right Grant
- 2013-06-05 EC ECSP13012664 patent/ECSP13012664A/es unknown
2014
- 2014-02-26 US US14/190,899 patent/US9120769B2/en active Active
2015
- 2015-02-25 CY CY20151100195T patent/CY1116043T1/el unknown
- 2015-04-16 SM SM201500095T patent/SMT201500095B/xx unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009063061A2 (en) *	2007-11-16	2009-05-22	Boehringer Ingelheim International Gmbh	Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use

Also Published As

Publication number	Publication date
TW201242960A (en)	2012-11-01
UY33701A (es)	2012-05-31
CN103228642B (zh)	2015-02-18
KR20130119939A (ko)	2013-11-01
CO6781480A2 (es)	2013-10-31
NZ609281A (en)	2015-02-27
ECSP13012664A (es)	2013-08-30
TN2012000117A1 (en)	2013-09-19
EA022406B1 (ru)	2015-12-30
CL2013001221A1 (es)	2013-11-08
AU2011323164B2 (en)	2015-07-23
CN103228642A (zh)	2013-07-31
RS53900B1 (sr)	2015-08-31
US8686149B2 (en)	2014-04-01
GEP20166481B (en)	2016-05-25
WO2012061708A1 (en)	2012-05-10
AU2011323164A1 (en)	2013-05-02
EP2635563B1 (en)	2015-01-14
CA2816136A1 (en)	2012-05-10
US20140249174A1 (en)	2014-09-04
TWI537258B (zh)	2016-06-11
ECSP12011788A (es)	2012-10-30
PH12013500879A1 (en)	2013-07-01
PE20140123A1 (es)	2014-03-02
ME02066B (me)	2015-05-20
SI2635563T1 (sl)	2015-04-30
DK2635563T3 (en)	2015-02-02
US9120769B2 (en)	2015-09-01
UA110807C2 (uk)	2016-02-25
HRP20150327T1 (hr)	2015-04-24
US20120157488A1 (en)	2012-06-21
SG189859A1 (en)	2013-06-28
PT2635563E (pt)	2015-04-13
PL2635563T3 (pl)	2015-06-30
AR083678A1 (es)	2013-03-13
EP2635563A1 (en)	2013-09-11
MX2013005069A (es)	2013-08-29
CY1116043T1 (el)	2017-01-25
HK1184144A1 (en)	2014-01-17
SMT201500095B (it)	2015-07-09
JP2013541592A (ja)	2013-11-14
ES2533833T3 (es)	2015-04-15
BR112013011095A2 (pt)	2016-08-02
IL225647A0 (en)	2013-06-27
EA201390643A1 (ru)	2013-11-29
AP2013006902A0 (en)	2013-06-30

Publication	Publication Date	Title
AP3521A (en)	2016-01-11	Crystalline forms of hydrochloride salt of (4a-r,9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1h-indeno [2,1-b]pyridine-6-carbonitrile and their use as hsd 1 inhibitors
ZA200905363B (en)	2010-05-26	Inhibitors of AKT activity
IL209488A0 (en)	2011-01-31	Inhibitors of akt activity
IL221823A (en)	2016-10-31	Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors
IL228642A0 (en)	2013-12-31	Combinations of Akt inhibitor compounds and Bemorphanib, and methods of use
IL221520A (en)	2015-07-30	Pyrolopyrimidine compounds as inhibitors 4 / 6cdk
EP2445885A4 (en)	2012-11-28	SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CHINESE INHIBITORS AND METHOD FOR THEIR USE
ZA201304646B (en)	2014-12-23	5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace)
EP2114388A4 (en)	2011-08-17	INHIBITORS OF AKT'S ACTIVITY
ZA201304756B (en)	2016-07-27	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP2303852A4 (en)	2011-12-28	ACTIVITY INHIBITORS AKT
EP2306825A4 (en)	2011-12-28	HAMMER OF ACT ACTIVITY
ZA201208895B (en)	2014-01-29	Bicyclic compound derivatives and their use as acc inhibitors
EP2134175A4 (en)	2012-01-11	HAMMER OF ACT ACTIVITY
EP2549874A4 (en)	2013-10-02	SUBSTITUTED IMIDAZOLE [1,2-B] PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
IL220153A0 (en)	2012-07-31	Inhibitors of akt activity
EP2303277A4 (en)	2011-08-17	HAMMER OF ACT ACTIVITY
EP2579872A4 (en)	2013-11-13	HAMMER OF ACT ACTIVITY
EP2303017A4 (en)	2011-06-15	HAMMER OF ACT ACTIVITY
ZA201300009B (en)	2013-09-25	Oral formulation of kinase inhibitors
EP2303258A4 (en)	2012-03-14	ACTIVITY INHIBITORS AKT
ZA201209648B (en)	2013-08-28	Crystalline forms of kinase inhibitors
ZA201209647B (en)	2014-02-26	Crystalline forms of kinase inhibitors
HK1190151A (en)	2014-06-27	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
HK1184073A (en)	2014-01-17	Oral formulation of kinase inhibitors